Champions Oncology Inc
NASDAQ:CSBR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Champions Oncology Inc
Selling, General & Administrative
Champions Oncology Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Champions Oncology Inc
NASDAQ:CSBR
|
Selling, General & Administrative
-$19.9m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-8%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Selling, General & Administrative
-$8.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
Danaher Corp
NYSE:DHR
|
Selling, General & Administrative
-$7.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-5%
|
|
|
Waters Corp
NYSE:WAT
|
Selling, General & Administrative
-$830.4m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Selling, General & Administrative
-$1.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Selling, General & Administrative
-$2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-8%
|
|
Champions Oncology Inc
Glance View
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Baltimore, Maryland and currently employs 194 full-time employees. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
See Also
What is Champions Oncology Inc's Selling, General & Administrative?
Selling, General & Administrative
-19.9m
USD
Based on the financial report for Jan 31, 2026, Champions Oncology Inc's Selling, General & Administrative amounts to -19.9m USD.
What is Champions Oncology Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-8%
Over the last year, the Selling, General & Administrative growth was -20%. The average annual Selling, General & Administrative growth rates for Champions Oncology Inc have been -5% over the past three years , -10% over the past five years , and -8% over the past ten years .
